OBJECTIVES: To describe treatment patterns and resource consumption in patients with MS-related spasticity in Germany.  METHODS: MOVE 1 (MObility ImproVEment) is a multi-centre, cross-sectional, retrospective burden-of-disease study and combines a 12-month chart documentation with a patient questioning at office-based neurologists, outpatients department at hospitals and rehabilitation centers. Data were collected on demographical and clinical characteristics, treatment patterns and resource consumption (e.g. drug treatment, physiotherapy, OTC products). Direct costs were calculated from payer’s (statutory health insurance) and patient’s perspective. RESULTS: In total, 419 patients were enrolled at 42 centers from 4-9/2011. 414 patients fulfilled selection criteria and were analyzed. Mean age was 48.6 (± 9.6) years, 64.3% were female. According to physicians 27.3% of patients had mild, 44.0% moderate and 28.7% severe spasticity. Onset of spasticity was on average 8.2 (± 5.9) years before study inclusion. At study inclusion, 55.1% of patients had ongoing antispastic drug therapy (of these 55.3% received baclofen). Percentages increased with increasing severity from 33.9% (mild) to 76.5% (severe). The majority of patients received drug mono-therapy (75.4%) or dual therapy (20.2%). Overall, 37.7% of patients had used OTC products and dietary supplements (of these 46.4% vitamins, 36.4% analgesics and 26.5% omega 3-fatty acids). Within the last 12 months, 78.8% of patients had received physiotherapy (mild: 66%; severe 86%). Mean costs per patient and year from payer perspective amounted to €908 (± 991) for physiotherapy and €244 (± 467) for drugs. Stratified by severity of spasticity, physiotherapy cost increases from €516 to €1351 and drug cost from €85 to €458. Patients spent on average €14 (± 28) for drug co-payments, €182 (± 208) for physiotherapy and €131 (± 319) for OTC products and dietary supplements per year. CONCLUSIONS: This study provides first real-life data on treatment patterns and resource consumption in patients with MS-related spasticity in Germany.